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Abstract
The objective of this study was to investigate the effect of beta blocker on cardiac recovery and rhythm during
cardiac surgeries. Sixty surgical rheumatic heart disease patients were received esmolol 1 mg/kg or the same
volume of saline prior to removal of the aortic clamp. The incidence of cardiac automatic re-beat, ventricular
fibrillation after reperfusion, the heart rate after steady re-beat, vasoactive drug use during weaning from bypass,
the posterior parallel time and total bypass time were decreased by esmolol treatment. In conclusion: Esmolol has
a positive effect on the cardiac recovery in cardiopulmonary bypass surgeries.
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Background
It has been well documented that early administration of
beta-adrenergic antagonist during CPB or within 10
minutes after releasing of aortic clamp contributes to
left ventricular function [1,2]. Also, cardioplegia con-
tained esmolol, an ultra-short acting (9-minute half-life)
cardioselective beta blocker [3], has cardioprotection in
animal model and clinical patients [4-7]. However few
studies have investigated beta-adrenergic antagonist on
the details of the cardiac recovery and rhythm during
CPB. In this study, we therefore investigated the effect
of esmolol on the cardiac recovery in rheumatic heart
surgeries.
Methods
The study protocol followed the Declaration of Helsinki
and was approved by the Ethics and Research Commit-
tee of Nanjing Medical University (Nanjing, P.R. China).
The study was performed in a prospective randomized
manner after all the patients signed written informed
consents.
60 rheumatic heart disease patients undergoing elec-
tive single mitral valve replacements were enrolled in
our study. Patients were randomly assigned to two
groups by a computer program. 30 patients received
esmolol (Qilu Pharmacy, China)1 mg/kg prior to
removal of the aortic clamp, while 28 received the same
volume of saline. 2 patients were excluded because of
cardiopericarditis. The cardiac recovery of patients was
assessed on the basis of:(1) the heart auto re-beat ratio
(the heart beat returns spontaneously without ventricu-
lar fibrillation or a temporary pacemaker); (2) the recov-
ery time (time from reperfusion to steady heart beat);
(3) the ratio of atrial fibrillation during weaning; (4)
Ventricular fibrillation after primary re-beat (5) heart
rate after steady re-beat; (6) heart rate 10 minutes after
re-beat, and (7) temporary peri-operative pacemaking,
(8) vasoactive drug use during weaning from CPB. We
also recorded the bypass associated time.
Statistical analysis
The data were analyzed with the software SPSS 11.0.
T h eq u a n t i t a t i v ed a t aw e r ee x p r e s s e da sm e a n±S D ,
and the difference was compared using one-factor analy-
sis of variance. The qualitative data were compared with
chi-square analysis. Fisher’s exact test was used when
the minimum expected count was less than five. P <
0.05 was considered to be significant.
Results
Following esmolol treatment, the heart underwent re-
beat automatically in 26 patients, as compared to 10
patients in the control group (P < 0.001). Ventricular
fibrillation after primary re-beat happened in 9 cases in
control but only 1 case in esmolol group (P = 0.005).
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ment group, and 4.4 ± 1.5 min in controls (P = 0.407).
The heart rate after steady re-beat was 89.6 ± 14.9 bpm
in control but 49.9 ± 14.6 in treatment group (P <
0.001). The heart rate after successful re-beat 10 min-
utes later was 94.8 ± 14.3 bpm in control but 91.5 ±
10.5 in treatment group (P = 0.310). Atrial fibrillation
was found in 11 cases in control and 10 cases in esmolol
group (P = 0.786). Two of the control group required
temporary pacemaker, compared to 3 patients in the
treatment group (P = 1.000). Eleven patients in control
group needed vasoactive drug during weaning from
bypass while only three in esmolol group (P = 0.014).
(Figure 1 to Figure 2)
Figure 1 The heart recovery data after unclamping. A: The auto re-beat ratio in the control group and esmolol group. (two black triangles) P
< 0.01 compared with control group. B: Ventricular fibrillation ratio in the control group and esmolol group. (two black triangles) P < 0.01
compared with control group. VF represents for Ventricular fibrillation. C: The recovery duration (time from reperfusion to steady heart beat) in
the two groups. min represents minute. D: Atrial fibrillation during weaning from CPB. AF represents atrial fibrillation. E: Temporary peri-operative
pacemaking use in the two groups. F: Vasoactive drug use in the two groups. (one black triangle) P < 0.05 compared with control group.
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Page 2 of 4The aortic-cross clamping time was 39.9 ± 9.1 min-
utes in control group and 39.4 ± 8.0 minutes in esmolol
group (P = 0.827). The posterior parallel time (time
from unclamping to weaning) was 29.6 ± 8.9 minutes in
control group and 24.3 ± 7.8 minutes in esmolol group
(P = 0.007). The bypass time was 69.9 ± 9.0 minutes in
control group and 63.7 ± 10.9 minutes in esmolol group
(P = 0.022). (Figure 3)
Discussion
Our study found a positive effect of beta blocker on the
prevention of ventricular arrhythmia in surgical heart
disease patients. In addition, we also identified that
esmolol increased the auto re-beat success rate,
decreased the incidence of ventricular fibrillation after
primary re-beat, and maintained better myocardial oxy-
gen delivery and consumption balance without prolong-
ing bypass time. On the contrary, esmolol treatment
prior to removal of the aortic clamp decreased the pos-
terior bypass time.
Esmolol treatment did not increase the need for tem-
porary cardiac pacemaker in order to maintain the tar-
get heart rate after bypass. Because it is a very short
acting beta blocker, and it seldom depresses the heart
rate or contractility when administered in the early
stage. In addition, esmolol improved the cardiac recov-
ery and the heart oxygen delivery and consumption bal-
ance, which increased the myocardial energy stores and
thereby benefit for the weaning process.
More and more physicians incline to use beta blocker to
treat various arrhythmias including ventricular arrhythmia
in non-surgical patients [8-11]. And in accordance with
those studies, we also found that beta blocker had positive
effect on the recovery and ventricular arrhythmias in car-
diac surgery patients, which indicated beta blocker was
another alternate to benefit the heart rhythm in CPB
patents. Although there are some studies and meta-analy-
sis about esmolol in cardiac surgery [12-16], most of them
are about CABG patients and about peri-operative compli-
cations. Ours is more detailed on the cardiac recovery and
heart rhythm during CPB intra-operatively, which is
almost scarce in the present clinical researches.
In conclusion, esmolol has a positive effect on the car-
diac recovery in CPB surgeries.
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